Sernova Biotherapeutics Inc
SEOVF
$0.12
$0.00-3.90%
OTC PK
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.39% | -10.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.70% | -32.21% | |||
| Operating Income | 9.70% | 32.21% | |||
| Income Before Tax | -9.31% | 44.98% | |||
| Income Tax Expenses | -34.09% | -357.14% | |||
| Earnings from Continuing Operations | -8.69% | 46.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.69% | 46.60% | |||
| EBIT | 9.70% | 32.21% | |||
| EBITDA | 7.71% | 31.78% | |||
| EPS Basic | -6.25% | 46.67% | |||
| Normalized Basic EPS | -6.45% | 45.61% | |||
| EPS Diluted | -6.25% | 46.67% | |||
| Normalized Diluted EPS | -6.45% | 45.61% | |||
| Average Basic Shares Outstanding | 2.34% | 0.07% | |||
| Average Diluted Shares Outstanding | 2.34% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||